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810-3 Prognostic Significance of B-Type Natriuretic Peptide in 
the Hemodialysis Patient
Haruki Itoh, Akira Koike, Keiko Oikawa, Hiroshi Kawaguchi, Yoichiro Tabata, Noriyoshi 
Murotani, Tomoko Maeda, Reiko Ishihara, Kaori Tajima, Long Tai Fu, The Cardiovascular 
Institute, Tokyo, Japan
Background: Although the population of maintenance hemodialysis has been rapidly
increasing and cardiovascular complications are their major cause of death, it has not
been clarified whether the circulating hormonal factors relate the mortality in these
patients.In the present study, we aimed to determine the prognostic power of plasma
natriuretic peptides in patients on maintenance hemodialysis, comparing with that of car-
diac function and the frequency of arrhythmias. The primary endpoint was all-cause mor-
tality.
Methods: Measurements of A-type and B-type plasma natriuretic peptides (ANP, BNP),
echocardiography, and 24-hour ambulatory monitoring of ECG were performed in 724
consecutive patients with maintenance hemodialysis (57 ± 13 yr). Plasma natriuretic
peptides were measured immediately before hemodialysis; ambulatory monitoring of
ECG was performed including a period of hemodialysis in all the patients.
Results: After two years of prospective follow-up, 88 deaths occurred. The plasma BNP
level was markedly higher in non-survivors than in survivors (mean ± SD;732 ± 860 vs
371 ± 434 pg/ml, p<0.0001). Plasma ANP level was also higher in non-survivors than in
survivors (229 ± 205 vs. 162 ± 214 pg/ml, p<0.0001). Left ventricular ejection fraction
was lower (62 ± 14 vs. 66 ± 11 %, p=0.0012) and premature atrial complexes during 24
hours were more frequent in nonsurvivors as compared to those in survivors. In the
univariate Cox proportional hazards model, all of these indices were found to be signifi-
cant prognostic indicators for survival. However, only high levels of plasma BNP revealed
to be a significant independent predictor when these indices were entered into a multi-
variate analysis. Kaplan-Meier survival curves demonstrated a survival rate of 59 % for
patients with plasma BNP>292 pg/ml (median value) and 81 % for those with plasma
BNP < 292 pg/ml, showing a significant difference in survival (p<0.0001).
Conclusions: These findings indicate that plasma BNP is the most useful index among
hormonal and cardiovascular variables for assessing the mortality in patients with main-
tenance hemodialysis.
11:45 a.m.
810-4 Pexelizumab, a C5 Complement Inhibitor, Reduces 30-
Day Mortality in Patients Undergoing Coronary Artery 
Bypass Surgery or Receiving Reperfusion Therapy for 
Acute Myocardial Infarction
Frans J. Van de Werf, Paul W. Armstrong, Jerrold Levy, Christopher B. Granger, Robert 
M. Califf, Peter X. Adams, Michael VanderLaan, Christopher Mojcik, Thomas G. Todaro, 
Edward D. Verrier, University of Leuven, Leuven, Belgium
Background: Complement activation may contribute to myocardial injury in patients expe-
riencing ischemia/reperfusion either from coronary artery bypass surgery (CABG) with
cardiopulmonary bypass or from reperfusion therapy (primary angioplasty or thromboly-
sis) for acute myocardial infarction (AMI). Pexelizumab, a single-chain monoclonal anti-
body against C5, given as a bolus and a 20-24hr infusion, was compared, double blind,
with placebo in 3,631 CABG (phase II: 606; phase III: 3,025) and in 1,274 AMI (primary
angioplasty: 643; thrombolysis: 631) patients. We performed an intention-to-treat analy-
sis of all-cause mortality at 30 days in the total population studied.
Results: Number of patients, number of deaths, relative risks (RR) and 95% confidence
intervals (CI) in the different studies and in the total population are shown below.
Conclusion: When compared with placebo, pexelizumab was associated with a signifi-
cant reduction in 30-day mortality in the total population studied. These encouraging
results support further studies with pexelizumab in inflammatory mediated disease states
in which complement activation plays a pathophysiological role.
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810-5 Use of Either Metformin or Thiazolidinedione Is 
Associated With Improved Survival Among Patients 
With Type 2 Diabetes From a Registry of 16,203 Diabetic 
Patients
Farangis Lavasani, Joseph B. Muhlestein, Dalton Einhorn, Robert R. Pearson, Heath U. 
Jones, Benjamin D. Horne, Tami L. Bair, Heidi Thomas, Dale G. Renlund, Donald L. 
Lappe', Jeffrey L. Anderson, LDS Hospital, Salt Lake City, UT, Sankyo Pharma, 
Parsippany, NJ
Background: Type II diabetes mellitus (DMII), mainly a disease of insulin resistance, is a
known risk factor for mortality. Management of hyperglycemia associated with DMII is
possible through a variety of medications including insulin supplying [exogenous insulin
(I) or sulfonylureas (SU)] or sensitizing [(metformin (MF) or thiazolidinediones (TZD)]
agents. It is unclear how these agents affect survival. The objective of this study was to
evaluate the incidence of all-cause mortality among patients (pts) with DMII based on the
type of diabetic medications prescribed.
Methods: An observational registry of 16,203 pts with a DMII admission ICD-9 code was
developed during the decade between January 1, 1992 and December 31, 2001 and pts
followed until July 1, 2002. Pt baseline clinical (including baseline glycosylated hemoglo-
bin A1C) and demographic characteristics were recorded and Cox regression controlled
for these multiple covariates. Adjusted all-cause mortality associated with the use of each
diabetic medication class was then compared with that of the entire population not taking
that specific medication.
Results: Information regarding discharge prescriptions was available on 8,004 pts. Of
these, 88% received I, 43% received SU, 20% received MF, and 4% received TZD with
many pts receiving multiples of these medications. Use of TZD (adjusted HR = 0.60 [95%
confidence interval (CI) = 0.40, 0.91], p = 0.015) and MF (adjusted HR=0.74 [0.62, 0.87],
p<0.001) were associated with significantly lower mortality than SU (adjusted HR=0.87
[0.78, 0.96], p=0.006) or I (adjusted HR=2.3 [2.1, 2.5], p<0.001). Insulin therapy was
associated with an especially worse outcome compared to no insulin therapy (adjusted
HR 3.0, p<0.001). Baseline glycosylated hemoglobin did not affect the results of this
study.
Conclusion: In this large observational study of patients with DMII, the insulin sensitizing
agents TZD and MF were associated with better survival outcomes than insulin-providing
therapies (SU, I). The possibility that this represents a causal relationship deserves test-
ing in prospective randomized clinical trials.
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812-1 C-Reactive Protein, the Metabolic Syndrome, and 
Prediction of Cardiovascular Events in the Framingham 
Offspring Study
Martin K. Rutter, James B. Meigs, Lisa M. Sullivan, Ralph B. D'Agostino, Sr., Peter W. 
Wilson, Framingham Heart Study, Boston, MA, Boston University Schools of Medicine 
and Public Health, Boston, MA
Background: Inflammation (assessed by C-reactive protein; CRP), and the Metabolic
Syndrome (MetS; by the NCEP-ATP III definition), have been linked to the development
of cardiovascular disease (CVD), but population-based data in men and women are lim-
ited.
Methods: Persons with diabetes or CVD at baseline were excluded. We analyzed the
cross-sectional relations of CRP to the MetS in 3037 Framingham Heart Study subjects
(1681 women, mean age 54 years), and used age-, sex-, and multivariable-adjusted
models to assess the utility of CRP and the MetS to predict incident CVD (cardiovascular
death, myocardial infarction, unstable angina, stroke or TIA) over 8 years of follow-up.
Results: The MetS (>3 of 5 traits) was present in 24% of subjects; mean CRP levels for
those with 0, 1, 2, 3, 4 or 5 MetS traits were 0.3, 0.7, 1.2, 2.3, 2.7 and 4.1 mg/L respec-
tively (age-adjusted trend p<0.0001). Among persons with >2 traits of the MetS, CRP lev-
els were higher in women than in men (p<0.02). CRP levels were higher in persons with
elevated BMI, waist circumference, abnormal CVD risk factor levels, and fasting hyperin-
sulinemia. There were 189 CVD events during follow-up; MetS and baseline CRP were
individually related to CVD events (age-sex-adjusted HR (95% CI): 2.1 (1.5-2.8) for MetS,
and 2.2 (1.4-3.5) for CRP comparing persons in the highest and lowest quartiles).
Greater risk of CVD persisted for MetS and CRP even after adjustment in a model includ-
ing age, sex, MetS (HR (95% CI): 1.8 (1.4-2.5)), and CRP (1.9 (1.2-2.9) comparing high-
est and lowest quartiles). The c-statistic associated with the age-sex-adjusted model that
included CRP was 0.72, for the adjusted model with MetS was 0.74, and for the adjusted
model including CRP and MetS was 0.74.
Conclusions: Elevated CRP levels are related to insulin resistance and to the presence
of the MetS. Higher CRP levels in women compared to men with the MetS might help to
explain the greater increase in CVD risk experienced by women with diabetes and pre-
diabetes. Although discrimination of subjects at risk for CVD events using both MetS or
CRP is not better than using either phenotype alone, both CRP and MetS are indepen-
dent predictors of new CVD events.
Placebo Pexelizumab RR (95% CI) p
CABG phase II 7/306 3/300 0.44 (0.11 – 1.67) 0.340
phase III 51/1508 41/1517 0.70 (0.48 – 1.12) 0.162
AMI primary angioplasty 16/315 7/328 0.42 (0.18 – 1.01) 0.055
thrombolysis 28/316 23/315 0.82 (0.49 – 1.40) 0.560
All Trials 102/2442 71/2460 0.69 (0.51 – 0.93) 0.016
